We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
-0.87%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$556M
AUM Growth
-$26.7M
Cap. Flow
+$17.2M
Cap. Flow %
3.09%
Top 10 Hldgs %
96.19%
Holding
17
New
1
Increased
2
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$136M
2
NUVB icon
Nuvation Bio
NUVB
+$28.4M
3
MRKR icon
Marker Therapeutics
MRKR
+$2.61M

Top Sells

Rank Stock Value
1
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$148M
2
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$2.01M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$374M 67.28%
6,068,125
+2,078,713
+52% +$136M
HRMY icon
2
Harmony Biosciences
HRMY
$2.04B
$27.8M 5.01%
842,815
– –
NUVB icon
3
Nuvation Bio
NUVB
$2.2B
$26.6M 4.78%
+2,541,009
New +$28.4M
SNDX icon
4
Syndax Pharmaceuticals
SNDX
$1.69B
$22.9M 4.13%
1,025,000
– –
SPRB
5
Spruce Biosciences
SPRB
$118M
$20M 3.6%
16,073
– –
ACRS icon
6
Aclaris Therapeutics
ACRS
$726M
$16M 2.88%
634,455
– –
SYRE icon
7
Spyre Therapeutics
SYRE
$8.54B
$13.4M 2.41%
67,646
– –
TECX
8
Tectonic Therapeutic
TECX
$529M
$12.8M 2.31%
84,148
– –
VRNA
9
DELISTED
Verona Pharma
VRNA
$11.1M 2.01%
1,332,485
– –
PSTX
10
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$9.96M 1.79%
1,043,267
– –
MRKR icon
11
Marker Therapeutics
MRKR
$18.8M
$7.04M 1.27%
314,286
+114,286
+57% +$2.61M
BCEL
12
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$5.94M 1.07%
387,653
– –
OBSV
13
DELISTED
ObsEva SA Ordinary Shares
OBSV
$4.51M 0.81%
1,386,338
– –
ZSAN
14
DELISTED
Zosano Pharma Corporation
ZSAN
$3.37M 0.61%
77,664
– –
NBRV
15
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$317K 0.06%
7,641
– –
VIRX
16
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-288,571
Closed -$2.01M
EIDX
17
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
– –
-1,123,630
Closed -$148M

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Aisling Capital Management held 17 positions worth $556M, down 4.6% from $582M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Aisling Capital Management deployed $17.2M of net new capital in Q1 2021, opening 1 new position and adding to 2 existing holdings. Its largest new stake was Nuvation Bio: 2,541,009 shares worth $26.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the most notable exit was Eidos Therapeutics, Inc. Common Stock, an estimated $148M sold.

  • Aisling Capital Management's largest Q1 2021 buy was Nuvation Bio: 2,541,009 shares worth $26.6M.
  • Aisling Capital Management added most to BridgeBio Pharma in Q1 2021, an estimated $136M increase.
  • Aisling Capital Management fully exited Eidos Therapeutics, Inc. Common Stock in Q1 2021, selling an estimated $148M.
  • Aisling Capital Management's ten largest holdings make up 96% of its $556M portfolio in Q1 2021.
  • Aisling Capital Management opened 1 new position and closed 2 in Q1 2021.
  • Aisling Capital Management's portfolio value fell 4.6% quarter-over-quarter to $556M.

Based on Aisling Capital Management's 13F filing for Q1 2021, filed 14 May 2021.